Abstract Metachromatic leukodystrophy (MLD) is an autosomal recessive, inherited, lysosomal storage disease caused by a deficiency in arylsulfatase A (ASA). This disease is characterized by progressive demyelination leading to severe neurological symptoms. Allogenic bone marrow transplantation at an early stage of clinical course is only effective treatment currently available. Accordingly the corrective transfer of the ASA gene into hematopoietic stem cells is thought to be an important option for curative treatment for MLD. We have recently developed a selectable vector system based on ex vivo sorting of transduced cells (Migita et al. 1995) . In this study, we applied this selectable system for development of MLD gene therapy. A bicistronic retroviral vector containing ASA cDNA and CD24 cDNA as a selectable marker gene was constructed. This vector was successfully transduced on fibroblasts from MLD patients, ASA activity was increased 7-fold compared to normal untransduced cells. PCR Southern analysis of hematopoietic colonies showed that transduction efficiency of CD34+ cells was 11-22%. However, after fluorescenceactivated cell sorting using anti-CD24 antibody, 75-100% of colonies became vector positive. The sorting raised the ASA activity several fold compared to untransduced CD34+ progenitors. These results suggest that a bicistronic ASA vector containing a CD24 selectable marker could be a useful component of gene therapy for MLD.
Introduction
Metachromatic leukodystrophy (#250100, MLD) is a lysosomal storage disease, caused by deficiency of arylsulfatase A (EC 3.1.6.8., ASA) which hydrolyses cerebroside sulfate (Kolodny and Fluharty 1995) . The disease is characterized by accumulation of cerebroside sulfate in oligodendrocytes in the brain resulting in demyelination. No effective therapy, other than the allogenic bone marrow transplantation (BMT), has been developed, and without BMT, patients usually die within a decade after the first appearance of the clinical symptoms. Earlier reports strongly asserted that it was crucial to perform BMT at a presymptomatic stage of MLD, to expect the best possible neurological outcome (Krivit et al. 1995; Hoogerbrugge et al. 1995; Malm et al. 1996) . Although the rationale of BMT in lysosomal storage diseases is not completely clear, one possibility appears to be cross-correction by transfer of normal enzyme from the donor cells to the deficient cells (Neufeld 1991; Olsen et al. 1981) . Unfortunately, HLA-matched donors are frequently difficult to find. This has made gene therapy strategy that targets hematopoietic stem cells (HSC), using autologous BMT, advantageous.
Gene transfer experiments using various viral vectors containing the ASA gene have been attempted (Rommerskirch et al. 1991; Ohashi et al. 1995; Learish et al. 1996) . Oligodendrocytes are important targets for gene therapy of MLD. However, there are many difficulties in stable gene transfer into neuronal cells at present. Retroviral mediated gene transfer into human HSC is an important option, but its efficiency remains very low. An alternative approach has been to develop methods for selecting transduced cells from non-transduced cells, using a selectable marker. We have developed a novel system in which a bicistronic retroviral vector, containing a surface antigen (human CD24) that serves as a selectable marker (Kay et al. 1991; Pawliuk et al. 1994) , is used to efficiently select transduced cells without exposure to the cytotoxic agents such as neomycin (Migita et al. 1995) . Because there was very good correlation between expression of therapeutic and marker genes, it was possible to select only genetically modified cells prior to transplantation therapy. This success has led us to search other target diseases. In the present study, we tested the ability to deliver the ASA gene into HSCs using a bicistronic selectable retroviral vector.
Materials and methods

Vector Construction
A plasmid pBEH/HT14-CP8 containing human ASA cDNA was a generous gift from Dr. Gieselmann (University of Kiel, Kiel, Germany; Stein et al. 1989 ). The ASA cDNA fragment was isolated from pBEH/HT14-CP8 by EcoRI digestion, blunt ended, and modified with XhoI linkers. This XhoI fragment was inserted into the XhoI site of pG1EC, which is a MoMLV-based vector plasmid bearing an internal ribosomal entry site (IRES) from the long 5Ј-untranslated region of encephalomyocarditis virus (EMCV), and human CD24 cDNA fragment between 5Ј-and 3Ј-long terminal repeats (LTR) (Migita et al. 1995) . The resulted plasmid was named as pASAEC.
Cell Culture, viral producer cells, and fluorescenceactivated cell storer (FACS) Transient ecotropic virus-producer cells BOSC23 (Pear et al. 1993) , amphotropic virus producer cells GP + envAM12, and NIH3T3 cells (American Type Culture Collection, Rockville, MD, USA) were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10 % fetal bovine serum (FBS), penicillin (100 units/ml), streptomycin (100 mg/ml) and 10 mg/ml of glutamine. Skin fibroblasts from the patients with MLD, which were a kind gift from Dr. Sakuragawa (National institute of Neurology and Psychiatry, Tokyo, Japan), were cultured in the same media but containing 15 % FBS. High-titer amphotropic virusproducing GP+envAM12 cells were created by multiple infections with ecotropic virus supernatants from BOSC23 cells transfected with pASAEC. These transduction procedures were repeated 15 times, and cells expressing high CD24 level were selected by fluorescence-activated cell sorter (FACS; FACS Caliber, Becton Dickinson, Tokyo, Japan) for efficient cloning. To detect the CD24 expression, transduced cells (1x106) were labeled with FITC-conjugated anti-CD24 antibody (Accurate Chemical & Scientific Co., NY, USA) then sorted from untransduced cells by FACS. At the last step, the highest-titer clone was selected by FACS again from 50 colonies cloned. The titer was determined by Southern blot analysis of transduced 3T3 cells to estimate proviral copy number in the target cells. Viral titers were expressed as copies per transduced NIH3T3 cells per ml of vector supernatant.
Transduction to the target cells NIH3T3 cells were transduced once with 1 ml of viral supernatants and 9 ml of standard medium with 4 mg of protamine sulfate (Elkins-Sinn, Cherry Hills, NJ, USA). MLD skin fibroblasts were infected four times, on consecutive days, with 5 ml of viral supernatant and protamine sulfate. Human CD34+ hematopoietic progenitor cells were isolated from cord blood by Dynal CD34 progenitor cell selection system (Dynal, Oslo, Norway) and transduced with the viral supernatant, protamine sulfate, Interleukin (IL)-3 (Kirin Brewers Co., Tokyo Japan), IL-6 (Kirin), and stem cell factor (SCF) (Amgen, Thousand oaks, CA, USA) for 4 consecutive days, as previously described (Xu et al. 1995) .
Measurement of ASA enzyme activity Cultured cells were harvested and washed twice in cold phosphate-buffered saline (PBS). They were then sonicated in double-distilled water, then centrifuged to eliminate cellular debris. After quantifying of protein using the Bradford protein assay (Bio-Rad, Tokyo, Japan), ASA enzyme activity were measured by colorimetric assay utilizing p-nitrocatechol sulfate (Sigma, St. Louis, MO, USA) as a substrate, originally described previously (Baum et al. 1959 ).
The activity was described as mg of 4-nitrocatechol/mg of total protein per h.
Colony-PCR analysis for CD34+ derived hematopoietic colonies
Colonies grown for two weeks on methylcellulose containing GM-CSF, SCF, IL-3 (Methocult GF4534; Stem Cell Technologies, Vancouver, Canada) were selected separately in standard PCR buffer containing 0.45 % of Triton-X and 0.45 % of Nonidet P40. To extract DNA, each cell suspension was lysed by incubation for 1 hour at 55°C with 30 mg/ml of proteinase K (Boeringer Mannheim, Indianapolis, IN, USA) , which was then boiled for 10 min. The PCR primers were as follows; sense strand oligomer; 5Ј-GCACCCCAGCTCTACCACTC-3Ј, antisense strand; 5Ј-CACAGCCACCGTCGCAAGGA-3Ј. PCR was carried out at 94°C for 5 min., then 30 cycles of 94°C (30 s), 55°C (30 s), 72°C (1 min.); final elongation was performed at 72°C for 7 min. Bands were confirmed to be specific for ASA cDNA using a non-radioactive PCR-Southern hybridization procedure. Visualization on Hybond-N+ nylon membrane (Amersham Life Science, Buckinghamshire, England) was accomplished using ECL system (Amersham).
Results
Generation of high-titer, bicistronic vector producer cells
A schematic diagram summarizing the structure of the retroviral expression vector, pASAEC, is shown in Fig. 1 .
Expression of both the ASA and CD24 genes was controlled by the MoMLV-LTR by placing the IRES and the CD24 selectable marker gene downstream of the ASA cDNA. Transduction of BOSC23 cells with pASAEC resulted in simultaneous high level expression of ASA and CD24 (data not shown). Amphotropic recombinant retrovirus producer cells GPASAEC were generated from GP+ envAM12 cells by repeated infection with ecotropic retrovirus supernatants of BOSC23 cells transfected with pASAEC. FACS and cloning techniques were used to select 50 GPASAEC clones expressing high levels of CD24. Six clones showed prominent CD24 expression on FACS. To select the highest titer vector producer cell clone, viral supernatants from GPASAEC clones were incubated with NIH3T3 cells, and transduction efficiency was estimated by CD24 expression with FACS analysis and ASA enzyme activity on transduced 3T3 cells. One clone, GPASAECno.13, showed the highest levels of ASA enzyme activity and CD24 expression in transduced 3T3 cells, as well as more than three proviral copies per transduced 3T3 cells per ml of virus supernatant in comparison with copy number control samples (data not shown). Therefore, the clone no.13 was chosen as the ASAEC vector producer cells in this study.
Transduction of MLD fibroblast
Skin fibroblasts from two unrelated MLD patients were transduced with the ASAEC vector. FACS analysis revealed efficient gene transfer, with a high level of CD24 marker gene expression in transduced MLD fibroblasts from both patients (Fig. 2) , while untransduced MLD fibroblasts had little CD24 expression. This result indicates that it is possible to neglect intrinsic CD24 expression in fibroblasts, as vector ASAEC exhibited effective transduction into human MLD fibroblasts. High levels of ASA activity were also detected in transduced cells; the highest value was 1366.5 ± 6.1 µg/mg protein per h, which was seven fold higher than ASA activity in untransduced normal skin fibroblasts (normal value rangefrom 139.1 to 202.1 µg/mg protein per h in our assay system)( Table 1) .
Transduction of human CD34+ cells
We next examined whether the ASAEC vector could be used to transduce human CD34+ cells derived from cord blood. Figure 3a , b shows representative FACS profiles of double-labeled, human hematopoietic progenitor cells on the fifth day after transduction with the ASAEC vector. Figure 3a shows the FACS profile of uninfected cells: Because these cells were maintained in the presence of IL-3, IL-6 and SCF for 4 days during the ex-vivo culture, some cells had differentiated and no longer expressed CD34. Figure 3b shows the transduced CD34+ cells: Appoximately 15% of these CD34+ cells expressed CD24. The fractions were sorted based on the expression of CD24 and CD34. Sorted and unsorted CD34+ cells were plated on methylcellulose separately, and 2 weeks later, hematopoietic colonies were picked and individually analyzed for presence of the vector using PCR. Many colonies were pooled together for ASA enzyme activity measurement. As shown in Table  2 , transduction efficiency for the complete sample of hematopoietic colonies was 11-22%, whereas the efficiency among the sorted colonies was 75-100%; thus, the DNA integration ratio was significantly increased by sorting based on the expression of CD24. As compared with nontransduced CD34+-derived cell colonies, the ASA activity in the transduced, progenitor cell-derived colonies was significantly elevated (1.7-fold) in unsorted cells and was further increased (4.5-fold) in the sorted cells (Fig. 4) . A significant increase in ASA enzyme activity was noted in the virustransduced fibroblasts (MLD fibroblast/transduced). Enzyme activity was measured in triplicate, and expressed as µg of 4-nitrocatechol/mg of protein per h. ASA activities of fibroblasts from non-MLD subjects ranged from 139.1 to 202.1 in our assay system
Discussion
We report here on the successful retroviral gene delivery of the ASA and CD24 genes to skin fibroblasts from MLD patients and to human CD34+ hematopoietic progenitor cells, using a bicistronic vector. Transduced cells were readily separated from uninfected cells by FACS based on CD24 expression, consequently this selectable system has the potential to be highly advantageous for the development of MLD gene therapy targeting hematopoietic progenitors. There are several reasons why gene corrected hematopoietic progenitor cells should be useful for the treatment of MLD. First, storage material may be taken up by the donor macrophages; second, hematopoietic stem cells may be able to differentiate into both microglia and macroglia in the brain (Eglitis et al. 1997) ; third, enzyme protein may be transferred from the donor cells to the patient's deficient cells including oligodendrocytes. Recently, Sangalli et al. reported that overexpressed ASA in transduced 3T3 cells was secreted into culture medium and taken up by co-cultured MLD lymphoid cells or rat oligodendrocytes (Sangalli et al. 1999) . Therefore, gene therapy involving autologous transplantation of genetically corrected bone marrow cells is an attractive approach for MLD.
Lately, green fluorescent protein (GFP) has been used in retroviral vector systems for the selection of transduced cells by FACS (Persons et al. 1997) . As this gene has been cloned from a jellyfish, Aequorea victoriaIn (Chalfie et al. 1994) , it may cause an immunological response when GFPoverexpressed cells are implanted in human. In contrast, the CD24 molecule is the human hematopoietic cell surface antigen and therefore, is immunologically inert. This appears to be an advantage of using the CD24 marker over other non-human selectable markers such as GFP, resistant genes of neomycin, and hygromycin.
Oligodendrocytes CD34ϩ cells were transduced with the ASAEC vector, sorted, and cultured in methylcellulose. Individual colonies were picked up, and DNA was analyzed by PCR-Southern using an ASA cDNA probe. The data represent the number of colonies positive for the transduced ASA gene/total colonies selected non-dividing cells . Adenovirus vectors are capable of transferring genes into oligodendrocytes (Ohashi et al. 1995) , but the gene expression is only transient. Nevertheless, it may be eventually be possible to use adeno-associated virus (AAV) vector (Berns and Giraud 1996; Daly et al. 1999) , but the packaging system will need to be further refined before clinical use is possible (Trempe 1996 ). An additional disadvantage of direct vector injection is that it mediates gene transfer into only a very limited area. Because demyelination and accumulation of metachromatic granules occurs in all areas throughout the brain in MLD patients, direct injection would seems to be an insufficient treatment protocol. Accordingly, a combination of retrovirally mediated ex-vivo gene transfer into hematopoietic progenitor cells and AAV-mediated in-vivo gene transfer into neuronal cells may be important for the effective gene therapy of MLD. Another potential option may be the use of neural stem cells as target cells of gene transfer, although there are many technical and ethical problem in this strategy. Methods have already been developed for transducing neural stem cells from rodents using retroviral vectors Martinez-Serrano et al. 1995) . Moreover, in canine multiple sclerosis model, focal demyelinations were prevented by transplantation of oligodendrocytes from normal embryonic dog (Archer et al. 1997) . Recent technical developments have made it possible to purify and culture the human neural stem cells (Sah et al. 1997) . Once the technical challenges associated with handling human neural stem cells are overcome, their transplantation combined with gene transfer could open the way to an effective new therapy of MLD.
